Tiumbio Co., Ltd.

In2gen Co., Ltd.

Ho Soon Lee

Hun-Taek Kim

Ji-Hye Lee

Dae-Kee Kim

In-Young Song

Yung-Jue Bang

Yong-Kook Kim

Jae Won Choi

Hong-Kee Kim

Seok-chan Kang

Jin-Wook Jang

Ho Chul Shin

The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising Factor VII (FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The composition can store FVII and a variant thereof stably at room temperature for a long period of time. Thus it can be used as a useful therapeutic agent for patients suffering from hemophilia or congenital FVII deficiency.

Pharmaceutical composition with improved stability containing factor VII fusion protein

The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.

Factor VIII polypeptide

Growing community of inventors

Seoul, Kenya

Ho Soon Lee